Key Points
- Insider sale: Kiniksa CAO Michael Megna sold 4,600 shares for approximately $369,380 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct holdings by 13.67% to 29,062 shares.
- Strong operating results: The company reported quarterly earnings of $0.30 per share, in line with estimates, while revenue of $243.6 million exceeded the $226.49 million consensus forecast.
- Positive analyst outlook: Wedbush and Canaccord raised their price targets to $99 and $98, respectively. Kiniksa has a “Moderate Buy” consensus rating and an average price target of $87.38, although several firms recently downgraded their ratings to Hold or Buy.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael Megna sold 4,600 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares in the company, valued at $2,333,678.60. This represents a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Stock Performance
NASDAQ KNSA opened at $80.47 on Friday. The firm has a market cap of $6.28 billion, a price-to-earnings ratio of 82.96 and a beta of 0.09. The firm has a 50 day simple moving average of $71.61 and a 200-day simple moving average of $57.21. Kiniksa Pharmaceuticals International, plc has a one year low of $35.06 and a one year high of $82.94.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting the consensus estimate of $0.30. The firm had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. Equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.
Analysts Set New Price Targets
KNSA has been the topic of a number of recent research reports. Wedbush upped their price objective on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 30th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 12th. Canaccord Genuity Group boosted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Finally, Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of "Moderate Buy" and a consensus price target of $87.38.
Get Our Latest Stock Report on Kiniksa Pharmaceuticals International
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LP increased its position in shares of Kiniksa Pharmaceuticals International by 26.8% in the 2nd quarter. Corient Private Wealth LP now owns 10,214 shares of the company's stock valued at $653,000 after purchasing an additional 2,158 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth $256,000. California State Teachers Retirement System lifted its position in shares of Kiniksa Pharmaceuticals International by 6,384.0% during the 2nd quarter. California State Teachers Retirement System now owns 2,721,648 shares of the company's stock worth $174,049,000 after purchasing an additional 2,679,673 shares during the last quarter. TD Waterhouse Canada Inc. grew its stake in shares of Kiniksa Pharmaceuticals International by 4.5% during the second quarter. TD Waterhouse Canada Inc. now owns 16,691 shares of the company's stock worth $1,049,000 after purchasing an additional 724 shares in the last quarter. Finally, Nykredit A S acquired a new position in shares of Kiniksa Pharmaceuticals International during the second quarter worth $34,000. Institutional investors and hedge funds own 53.95% of the company's stock.
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
